

# THE PANDEMIC'S UNRESOLVED INFECTIOUS PSYCHO-NEURO-IMMUNOLOGIES: MYELOID CELLS, VESSELS, NASAL CROSS-ROADS

Gottfried R. S. Treviranus

BipoSuisse, Vereinsweg 11, CH 3012 Berne, Switzerland

## SUMMARY

Unresolved infectious psycho-neuro-endocrino-inflammation (PNEI) denotes an area of tragically accelerated interest because of SARS-CoV-2's capacity to meddle with the immune responses in a stage-wise fashion. Its pandemic, interacting with antecedent further deteriorating health and living conditions, takes a direct toll of million human lives. In order to withstand the plethora of slowly or never easing ailments labeled "Post-acute Sequelae of Covid-19 (PASC)" a comprehensive understanding from the intrusions up to its emerging aftermaths is paramount. For the strained health professions these prospect care requirements of 1 in 5 for a non-convalescence overlapping also with other tedious long-hauling "triggered" disorders adjacent to psychiatry like chronic fatigue with orthostasis intolerance or intracranial hypertension (ME/CFS-OI; IIH). For the latter two new pathophysiology are proposed in order to inform a strong rehabilitative psychiatric liaison not referring sufferers to a psychiatric "enigmo-somatic bin", but to an invigorated somato-psyche care e. g. for exertional malaise. Starting from early stimulation of escalating myeloid-derived suppressor cells the neglected mast cells show up (for now without their lymphatic partners) as ambivalent core participants. They interact or orchestrate or sequentially explode in etosis guarding or breaking sane barriers especially at cerebral arteries. In Covid-19 they seem unleashed at the blood-brain-barrier by the early virally invaded nasal ganglia, which plausibly mis-direct the quickest interstitial arterio-intramural outflow – thus a.) losing its ability to "comply" with pulsatile flow through varying the width of its sliding chambers causing ME/CFS-Orthostatic Intolerance and b.) inflaming and stiffening the brain's interstitium through a "push-back" outpacing the confuted inventive "glymphatic-1.0" model. Mast cells – colonized or not – plausibly permeabilize the choroid plexus and venous or bony brain barriers co-causing the not so rare Idiopathic Intracranial Hypertension. Innate memory - as activated by short RNAs through BCG-vaccinations directed against the permanent TBC-pandemic leads to hopes for a hastening of resolutions through a combined medical, exertional, psychosocial, and psychiatric rehabilitation informed by a new "PNEI" – paving the way for amplified-BCG or future psychiatric vaccinations.

**Key words:** SARS-CoV-2 – PASC – PNEI – ME/CFS – orthostasis intolerance – IIH – PPG – mast cells

\* \* \* \* \*

## INTRODUCTION

*"The truth is rarely pure and never simple."  
Oscar Wilde*

Here we present a cross-over from a broad-based attempt to come to grips with the pandemic's long-term challenges in order to better delimit the role of mental health care. Most references are omitted but can be retrieved on a preprint (with DOI-names at [www.biposuisse.ch/Perugia](http://www.biposuisse.ch/Perugia)), while a full paper is to be published this year.

### After the still sweeping defeat: reconstruct and prevent better

Mental health publications quickly dealt with Covid-19 psychologically, while "neuropsychiatric" trails below 4% and global mental health - as crucial as neglected (Adhanom Ghebreyesus 2020) - crawls. Large efforts from its workforce shall increase agency under "climatic" crises (Ripple 2020, Lynas 2020) – which abysmally decrease prospects for the young. The Covid-19-pandemic resulted as much from societal shortcomings (Casesmeiro Roger 2021) as from the SARS-CoV-2' immune subversion especially of the, often too resilient – but "Do-Not-Resuscitate!"- hampered (Alhajem 2020, Sutton 2020) – elderly (Levin 2020).

Psycho-Neuro-Endocrino-Immunology (PNEI) covers, also infectious, bio-psycho-social resilience to "stress" (Peters 2021). To understand Post-acute Sequelae of Covid-19 (PASC) "unresolved infectious PNEI" – involving neuro-interacting (Xu 2020, Selye 1965) mast cells (MCs) - proves essential (Bonneau 2007) (Table 1).

### How the pandemic takes inequalities further

SARS-2- seropositivity or anxio-depression in "lock-down" were best predicted by *prior* traumatic life events - besides male sex, smoking, family case(s) or autoimmunity. SARS-CoV-2 (SARS-2) targets patients who are: aged, obese, mentally ill, socio-economically, ecologically (H. Wu 2020) threatened, devoid of access to and/or providing health-care themselves (Bryant-Genevier 2021, Salazar de Pablo 2020) and, milder, expecting mothers – conditioning offspring (Lins, 2021) – and rarely children as multi-system-"MIS-C".

### "Long" Covid-19 - never to end?

While knowledge follows the surge of vaccines, carers fear the "#long-Covid-19" "for years to come". Such after-effects persisting beyond 2 months (Nalbandian 2021) are ascribed variously to: A. the *infection itself* (in- and outside the brain with its immune- thrombotic

**Table 1.** Psycho-social and biological stresses derail various neuro-immune responses

STRESS		Resilient Stress & Immune Response				Maladaptive Stress & Immune Response			
Responder	SYMP	PSymp	HPA	N-peptid / N-troph	SYMP	PSymp	HPA	N-peptid / N-troph	
Tr.mitter	NA/ADR	ACh	Cortisol (↑ CUS)		NA/ADR	ACh	Cortisol		
CNS	Constructive = positive MOOD				Destructive = negative MOOD				
BODY	Staged balances of BARRIERS, homeostases, IR-cells responses, repair → RESOLUTION				Derailments: at BARRIERS, of homeostases, IR-cell responses, repair → NON-RESOLUTION				
MCs	CNS-arteries: Abluminal, tonically inhibited				MCET, CK-crumbs → LYMPH-NODE activation				
LYMPH	Isolation of inflammatory cauldron				Neural opening of LYMPHATICS. MC egress.				
SARS-2	Elimination				Entries / Sanctuaries → Spreading.				

Modified after Fig. 2 (Peters et al., 2021). SYMP vs. PSymp: sympathetic versus Parasympathetic system; HPA: hypothalamic-pituitary-adrenal axis; CUS: Chronic Unpredictable Stress; ACh: Acetyl-Choline; NA/ADR: Nor-Adrenalin; NKcell: innate NATrual Killer cells; TH1/TH2: T-helper cells type 1 or 2; Treg: regulating T-cells; N-peptid / N-troph: Neuropeptides, Neurotrophins; INFγ: Interferon γ; IR: Immune Response; TJ-barrier: Tight junctions “gluing” barriers.

response), B. its *initially or subsequently* triggered *immuno-pathogenetic (viral)-stress cascades*, C. less to *primary* neuro-psychiatric microbial lesions and epigenetics, D. to what severe *psycho-social stress* damaged: loneliness preventing some substance-abuse and obesity increasing Covid-19-mortality, in contrast to mental illnesses. These seemingly secondary long-term mental health stresses induced many to abandon healthy habits and equitable ratiocination, dishearteningly increasing vaccination hesitancy.

### THE COVID-19-PANDEMIC FROM SARS-COV-2: A RAPID SURVEY

By imperfect testing (Rhoads & Pinsky 2021) SARS-2 was reported from Italian sewage weeks (La Rosa 2021, Fongaro 2021) and from serologies months (Apolone 2020, Chossegras 2020) before the “first” case. Covid-19 proved much faster-spreading: rapidly exceeding the predecessors’ (mental) services’ loads (Szcześniak 2020).

#### Straight from hell?

The closest relative SARS-CoV-1 (SARS-1) had been recovered in 2003 by the same “WIV”, Wuhan Institute of Virology, (Hu 2017) from interferon-“stuffed” bats, motivating an admonishment to prevent: a) further pandemics – as before when H1N1-influenza leaked from a Chinese (Wertheim 2010) or SARS-1 repeatedly from East-Asian labs - and b) the dangers of “gain-of-function” (in species-specific contagiousness) research (Cyranoski 2017). The latter was nevertheless pursued at WIV through international funding and now refers to the Swiss ABC-lab (Williams 2021). Already the surprisingly simultaneous mutations leading to

Covid-19 – close to bats’ SARS by sequence, and to pangolins’ SARS by binding domain – could have been engineered by insertion of a novel furin site (Segreto & Deigin 2021). Albeit this might not have occurred (Cyranoski 2020, Kramer 2021), the future tempting power and the hazards (Weiss 2015) exerted by such engineered mutations are gigantic, whereas their original motivation (since before 2000) has become obsolete by vaccinology’s speed-up. By another lab early Covid-19-patients from the animal-selling market received first-aid (Huang 2020). The spread within most countries was weakly opposed because of a puzzling lack of perception of the long persistence of PVJ- but not chlorhexidine-sensitive SARS-2 (Peletier 2021, Davies 2021, Shewale & Ratcliff 2021) on nasal and tongue mucosae, on shoes and malls, and on UV-sensitive conversational micro-drops filterable by non-sterile masks (Howard 2021).

### COMING TO KNOW THE COVID-19-DISEASES BY THE CLEVER SARS-COV-2

Covid-19 presents as a lung-focused, yet generalized (micro-)thrombotic disease involving all organs - whereby thrombi conform to arterial walls (Fahmy 2021). All this and a “misfiring” pro-inflammatory cytokine (PIC) “storm” (here PICKS) seemingly takes origin from a “emergency myelopoiesis” within bone-marrow whereby persistently stimulated special neutrophils and monocytes (Veglia 2021) exert potent immuno-suppressive, but also health-promoting, activities as myeloid-derived suppressor cells (MDSCs), which in Covid-19 disrupt NKcell and T-cells, but not B-cells. MCs augment various MDSC-activities.

**Table 2.** Human CoV-Variants: Escalating to ARDS, persisting in chronic aftermaths

<b>Human ARDS &amp; Coronavirus Diseases: gradation and temporal dynamics.</b>					
<b>Disease:</b>	<b>Initial</b>	<b>Advanced</b>	<b>Severe</b>	<b>CNS / LC-19</b>	<b>Sources</b>
ARDS { $\uparrow$ miRNA-146a miRNA-155}	Into Pneumo- cytes II: PICs	M $\phi$ : PICs damage EC	Alveol. flooding PMNs	[Delirium] (Psych. GAD MDD) fibrosis	Rabaan 2020 Badraoui 2020 [Kalra 2021]
MERS via DPP4 1000 by 903 d	Fever, Throat	Chest pain <i>stroke, GBS</i> <i>Bickerstaff, encephalitis</i>	ARDS Chest pain		Y Guo 2008 (Liu 2021) Zubair 2021 {Y Han 2016}
SARS-1 1000 by 130 d	Myalgia, Gut Headache	<i>encephalitis, stroke,</i> <i>GBS</i>	ARDS $\rightarrow$ neurons glia		
<b>Covid-19 via ACE2 x clathrin</b> 1000 by 48 d	Fever, Cough Dyspnoea. Gut, Myalgia [eos $\downarrow$ ]	Chorioid plexus: SARS+ <i>Trv.myelitis, DM AC-4</i>	ARDS		ISARIC 2021 [Outh 2021]
Covid-19 (H): CNS	Anosmia 48%	Anosmia $\rightarrow$ $\downarrow$ 7%	30% :SubArach- noid bleeding; 10% Stroke	Uncoord. 3/4 Paresis 1/2	Ermis 2021
Covid-19 (+3m)		<b>GM:</b> $\uparrow$ OLFCX, R&L_HC, INS, HESCH, L_OPERC, R_GGING [corr. $\downarrow$ Memory] <b>WM:</b> $\downarrow$ MD, $\downarrow$ AD, $\downarrow$ RD, $\uparrow$ FA	Sleep 2/3, Fear 1/2 PTSD 40%, MDD 1/3 Soma.1/3 Anx 1/6		Y Lu 2020 <u>Dong 2021</u>
Covid-19 Asymptomatic:	$\uparrow$ Ribosomes $\uparrow$ T-cells $\uparrow$ B-cells $\uparrow$ cell-killing (-)Th1-/Th17	INF- $\gamma$ or classic-complemental $\rightarrow$ $\uparrow$ Th17-boosting Nphs $\uparrow$ $\uparrow$			YH Chan 2021
	<b>Only Envelope-E2 proteine attack pore <math>\rightarrow</math> ARDS</b>				<b>B Xia 2021</b>
Covid-19 (H)	$\uparrow$ - $\uparrow$ $\uparrow$ : MIP-1A, IL-7, IL-2, IP-10, G-CSF, IL-10, MCP-1, TNF- $\alpha$				C Huang 2020
Covid-19 (H)	$\uparrow$ - $\uparrow$ $\uparrow$ : (CD14+)CD16+ monocytes rel. PICs				
	$\uparrow$ - $\uparrow$ $\uparrow$ : CXCL9, CXCL10, CXCL11 dep on Akt				Callahan 2021
Covid-19 (H)	<b>IL-1<math>\alpha</math>, IL-1<math>\beta</math>, IL-6, IL-10, IL-17A, IL-12 p70, IL-18, IFN<math>\alpha</math>, TNF</b>		<b>IL-33, IL-16, IL-21, IL-23, IFN<math>\lambda</math>, thrombopoietin, eotaxin/-3</b>		C Lucas 2020
<b>MIS-C by ADE</b> Age: 0;1-7;0-15;0 1f:2m <b>1. Vaccinations</b> Train immunity <b>2. Coinfected: &lt;1/2</b> <b>3. immature ACE2</b> <b>4. immature PICKS</b> <b>5. [MC deficiency]</b>	<b>Interval:</b> <b>4-5 weeks</b> Conjunctivitis Cough (1/3) Fever (27%) <b>Serum+: 82%</b> PCR+: 1/3	<b>95% <math>\rightarrow</math> 80%:</b> <b>Cardiovascular shock</b> <b>90% <math>\rightarrow</math> 70%:</b> Gut <b>35% <math>\rightarrow</math> 70%:</b> Lung <b>60% <math>\rightarrow</math> 40%:</b> Skin Rashes <b>7% <math>\rightarrow</math> 21%:</b> Kidney <b>15% <math>\rightarrow</math> 45%:</b> MAS / HLH <b>20% <math>\rightarrow</math> 7%:</b> CNS / PNS	ICU 1/3  <b><math>\leftarrow</math> Note:</b> $\rightarrow$ : Change of prevalence from ages [0;0 – 12;0] $\rightarrow$ 13;0 – 18;0].	1-2% sequelae	F Haslak 2021 Lo 2021 Q Wu 2020 [Springer 2019]
ACE2: ARDS/SCZ: ARDS in schizophrenia; DPP4: Dipeptidyl peptidase 4 receptor; ADE: Antibody-dependent Enhancement; EC: Endothelial cell. CHPLX+: Choroid plexus positive for SARS-CoV-2; CNS.vascular: Cerebrovascular; GBS: Guillain-Barré-Syndrome / Bickerstaff. GAD: Generalized Anxiety Disorder. (H): In-hospital-patients. MDD: Major Depressive Disorder.M $\phi$ : macrophage; MAS: Macrophage activation syndrome, HLH-like variant: HLH: "Hemophagocytic Lympho-Histiocytosis". MIS-C: Multisystem Inflammatory Syndrome-Children. PIC: Proinflammatory Cytokine; PICKS: PIC "Storm". (Lu 2020): OLFCX: olfactory (piriformis) cortex; HC: hippocampus; INS: insula; HESCHL: Heschl's gyrus, OPERC: operculum Rolandi; GCING cingulate gyrus. GM: grey matter; WM: white matter. AD: axial diffusivity; MD: water movement; FA: fiber anisotropy.					

Hereafter MCs provide the alveolar septa with anti-viral PICs becoming triggered by platelets and their activation factor (PAF) – which MCs secrete unless inhibited.

PASC – beyond convalescence – instead stems from an enduring low-level inflammatory state engrafted on also other antecedents or secondary infections – overlapping with 1-in-3 post-sepsis Chronic Critical Illness.

### **Covid-19 – the SARS-CoV-2-disease – by mast cells?**

After the first-week Covid-19-flu diversifies among 20 truly infected humans - strongly following host factors - into 3 paths of critical and 1 of severe illness, of which 2-4% perish under intensive care. Sputum correlates two-fold with mortality, the high-density ACE2 tongue and nose being the entrance area – unless PV-iodine is used (Carrouel 2021) (Table 2).

Covid-19 presents as an ARDS-prone inflammation from hyper-thrombotic and hypo-fibrinolytic events around endothelial cells (EC), their progenitors and «neighboring cells» derailing into PICKS, while early SARS-2-invasion of pneumocytes-II via macrophages (Mφs) can cause the alveolar endothelial edema of “ARDS”. This pneupathy initially results from – chromoglycin-sensitive – protease-liberating degranulations of MCTCs triggered by coupling of SARS-2’s spike-RBD with ACE2 (also impeding ACE2 to moderate through angiotensin-1-7), with directly and translationally pro-inflammatory and TJ-cracking effects (Wu 2021).

Despite SARS-2’ ubiquitous presence severe damage by perivascular infiltrations and viral intrusion in fact may arise only later (Remmelink 2020, Achermann 2020), when virus-infected MCs selectively recruit anti-viral innate NK-cells (Portales-Cervantes 2019, Savoy & Boudreau 2019).

### **Better (not) be a child for once: Multisystem Inflammatory Syndrome**

The respiratory ACE-2-docking points develop with age. COVID-19 is usually transient in children and PASC similarly abates. Rarely “MIS-C”-Covid-19-illness with nausea (¾), fever and shock recurs a month after the normo-pediatric rapid antibody response. MIS-C derailing via HMGB1-RAGE or by delta-hyper-replication is plausibly due to an invasion via “antibody-dependent enhancement” involving MCs (Wan 2021, Rieke 2020, 2021). IL-27-elicited MIS-C (Si 2018) (re-)damages gut (4/5), skin, conjunctivae (1/2), and the brain (40%) with pathognomonic Kawasaki-like cardiac failure (2/3), strawberry-tongue (4/5), and coronary ectasias. Its adult version causes obnubilation, dysautonomia, urticaria being treatable as an MC-activation (Theoharides & Conti 2020).

## **COVID-19 AND THE BRAIN**

Coronaviruses (CDC) rarely cause neuro(myelo-)degeneration. 1-in-3 struck by MERS- or SARS-1 suffered delirium (28%) or common hypomania, persisting in half over months with unstable memory or mood. After the three pandemics combined moderate anxio-depression and PTSD (Boden 2021) occurred throughout months among all (1/6), quarantined or healthcare-providers (1/4), and especially the ex-recovered (40%). Yet after Covid-19 most «recover without experiencing mental illness» (Rogers 2020; Gramaglia 2021).

Acutely SARS-2 too may aim at the brain, the other (humanCoV-HKU1/ OC43 / NL63/ 229E) coronavirus’ neuro-pathologies being variegated with rare pathogenic spreads “through axons” (Dubé 2018, Butler 2006). Access through the BBB is provided neither by stress (Roszkowski & Bohacek 2016, S Lee 2018) nor through maybe CSF-increasing leaks in infected organoids (Pellegrini 2021), nor through the naso-intestinal (Cataldi 2020) or olfactory path (Butowt 2021) - reaching unconnected parenchyma in hACE2-mice “through VR-spaces” (Cheng 2020) - perhaps if used by MCs.

### **Cerebral Covid-19: symptoms, clinical imaging, and pathology**

Neuro(-psychiatric) acute Covid-19 (Rogers 2021) presents with anosmia/dysgeusia (40%) – which are *half* as common in severe Covid-19 (Purja 2021) – and aching fatigue, with rare anxio-depression - acute encephalitis being relegated to sepsis (Tong 2021). Brain-imaging remains blind in 40% to multi-scale subcortical, meningeal, or white matter disturbances, with thrombo-vasospastically compromised cortical, yet high cerebellar perfusion. While neuro-diseases are rare, immune-pathology can follow mild Covid-19. Post-mortem microglia interacting with often infiltrated NK-cells appears altered, “profound nodules” denoting mild encephalitis. Non-destructive Covid-19 neuro-spectrum overall spares the frontal lobes, destruction requiring more, external, insults (Matschke 2020).

### **What opens the blood-brain-barrier first in Covid-19? Mast cells?**

A tough barrier to understanding remains the “cracking” of the initially sane blood-brain-barrier (BBB), normally only traversable for MCs, which “despite their small number activate all components of the neurovascular unit” (Silver & Curley 2013, Traina et al. 2017). Because late PICKS will *not* explain the commonly early neuropsychiatry of Covid-19, the BBB’s secondary disturbances (Hernández-Fernández 2020) must result from initial still dubious direct immune-attacks and occasionally “Trojan” viral intrusions (Morgello 2020). SARS-2 (packed in vesicles) do invade some neurons (Gu 2005, Zubair 2020, Paniz-

Mondolfi 2020), rather than ECs of the plexus choroidei and ventricles, which otherwise could provoke Idiopathic Intracranial Hypertension (IIH). Research, including such on CSF remains tenuous. SARS-2, measuring 100 nm (5-fold the size of “cracked” para-cellular pathways) requires vesicular transcytosis (Erickson 2021, Rapoport 2000). In vitro SARS-2 destabilizes the BBB: spike proteins cancel mRNA of tight junctions (TJs) and boost IL-6 or ACE2 on ECs (Reynolds & Mahajan 2021).

SARS-2 after docking onto membranous ACE2/Co-factor-points – beyond just injecting its RNA - *must* (not can) use clathrin- mediated (or putatively other) endocytosis (Bayati 2020, Petersen 2020, Yang & Shen 2020) which phenothiazines can block (Plaze 2020). SARS-2 attaches super-efficiently (Ellis 2021) through ACE2 which in differential brain regions is present on most also endothelial cells (H. Xu 2020), but occasionally too sparsely on MCs (Gebremeskel 2021) and other leukocytes to permit “Trojan” entries across the brain’s barriers (Desforges 2019, Generoso 2021). Yet on MCs spike-RBD binding to ACE2 SARS-2 triggers degranulation and pneumonia (Wu 2021, Komaroff & Lipkin 2021). Covid-19 through multiple mimickries of human brain epitopes promotes autoimmunity (Gupta & Weaver 2021), again intensified by MCs (Brown & Hatfield 2012).

Much of the PNEI-literature pivots around the short-living «extremely unspecific» (Himmerich 2019) PICs. Yet about their access to the healthy cerebral parenchyma across the BBB - facilitated by “circulating factors” - “little is known” (Erickson & Banks 2018). An authoritative reference on «sickness behavior» cited five modes of access (Capuron & Miller 2011): 1.) pseudo-«humoral»: via choroid plexus and the circumventricular organ - only if concentrated (Walker 2013); 2.) saturable trans-endothelial: to-and-fro (Banks 1989, Erickson & Banks 2019); 3.) pseudo-transport: eliciting substituting luminal endothelial PICs (Watkins 1995); 4.) «neural» conveyance of PIC-signals: via vagal afferents (Maier 1998); 5.) pseudo-«cellular» carriage by monocytes sucked in after TNF- $\alpha$ . To this own proposals can be added of 6.) peripherally imprinted MCs entering the sane brain after intruding counter-current along abluminal arterial pathways (Treviranus 2017) deranged 7.) by the “nasal” pterygopalatine ganglion (PPG) damaged by SARS-2.

Also PICs-stimulated MCs - via the “RAGE/NF- $\kappa$ B”-pathway - release further PICs and recruit MCs while the BBB opens. RAGE - which also senses microbial alarming “patterns” granting them access – opens and inflames barriers through MMP-9. In humans (and mice) cerebral ACE2-receptors (but not TMRSS) - very sparsely in the hippocampus, and *not* in the PFC- are found on neurons - and some companion cells. For the initial parenchymal access the EC’s ACE2-expression is crucial and high in the choroid plexus - determining CSF-pressurization and potential viral spreading- or in the paraventricular thalamic nucleus - a

hub for appropriative behavior, wakefulness, and stress-resilience controlled by intruding MCs (Treviranus 2017, Fitzpatrick & Morrow 2017, Ren 2018). Meanwhile SARS-2-replication within, also sanctuary-resident, monocytes/M $\phi$ s – also in “Trojan horse” modes of cell-trafficking move centerfold (Yilla 2005, Nikitina 2020).

## IMMUNOLOGICAL ANTI-SARS-COV-2-RESPONSES IN COVID-19

SARS-2 interacts with all adaptive immune cells, but T-cells seem to take the brunt with an often lethal dip (Zeng 2020). Again MCs orchestrate CD4+-T-cells by antigen-presentation (Li 2016). Within non-recovering lungs CD8+-T-cells maintain cytotoxicity via type-1-CKs and IL-17- with little resolving IL-10 from B-cells, who’s antibody-excesses become deleterious. Covid-19 astonishes through widely perceived immunological anomalies, maybe provoked by envelope-protein E2, alone causing ARDS via attack pores (Xia et al. 2021). Anti-viral responses against SARS-2 are brought about atypically by PICs related to type-2-interferon (INF) - but sparsely by type-1-INF needed against SARS-1, MERS or Influenza-A. While the asymptotically infected show protection through active ribosomes, T-cells, B-cells or cell-killing, but low Th1-/Th17-cytokines, acute Covid-19 shows innate and adaptive-Th2-hyper-responses to INF- $\gamma$  escalating into a “pro-inflammatory cytokine storm” (here PICKS), run up within white adipose tissue, ECs or pericytes – with running “deviated” *not* anti-viral (Méry 2020) Th17-cell responses. Research about PICKS traces “cytokine signatures” along cascades, long-non-coding RNAs or derailed antibody-productions, paralleling similar RNA-virus-diseases.

## Mast cells as candidate relevant players at the brain’s barriers

MCs are about to solve the conundrum, that the BBB in neuro-Covid-19 appears as disturbed without visible contributing cellular events. Although MCs have long been proven guardians at the “immune gate” to the brain (Theoharides 1990), they are neglected in relation to Covid-19 even by the pioneers.

Only the long-lived MCs are able of sequential “non-suicidal” eiosis (MCET) - forceful expulsions of nuclear anti-microbial material provoking micro-macro-immuno-thromboses (Bonaventura 2021) - in proportion to stimulations by microbes (Komi & Kuebler 2021). This could generate focal transient intramural serial explosions, with rapid resolution as in MIS-C - or autism and atherosclerosis (Theoharides & Zhang 2011; Pertiwi 2021). Peri-intra-arterial MCET could well open sufficient leaks for SARS-2 to enter the parenchyma, the more as MCs are present along the 600 km of microvessels (Guimbal 2021) being abluminal residents of the arterial media – suffering from putative push-backs from failing arterio-intramural clearance and

possibly being restrained tonically via muscarinic PPG-efferents (Trevisanus 2020) – unless suffering early attack by SARS-2 (Fagre 2020). MCs are hereby exposed to the wringing mechanisms of reverse intramural flow (CIMURAF, Trevisanus 2019) and to their newly discovered domino-activation of TNF- $\alpha$  production through extracellular vesicles (Vukman 2020). MCs also cooperate closely with the “lymphatic cauldron” which opens in sepsis (Oliver 2020, Kunder 2009, 2011).

### **What the Dengue-virus teaches about Covid-19**

Human MCs (without being invaded and unless blocked by stabilizers) after (granny-tyring) dengue-illness become “Th1-polarized” permeabilizing ECs the more their Fc $\gamma$ -receptors absorb immune-complexes, which have been cleared by apheresis improving PASC, whereas dengue-infected MCs – besides performing antigen-presentation to unconventionally responding ( $\gamma\delta$ )T-cells (Mantri & St. John 2019) – the kind becoming decreased in severe Covid – make vessels leak through many mediators. MC-stabilization rebalances (immuno)-metabolism (Morrison 2017). Via MMP9-gelatinase MCs disrupt the ischemic BBB.

### **A prime role for mast cells and arteries in cerebral Covid-19?**

Cerebral mast cells (CNS-MCs) besides residence-specific features lack IgE-, IgA-, and c-kit-receptors. Despite their unique faculties in entering the sane brain (Silvermann 2020, Silver & Curley 2013) – in contrast to M $\phi$ s (Lee 2021, Arcuri 2019) – MCs remain rarely discussed, and never as hypo-“activated”. Yet all previously MC-“overactivated” patients from a first global mild-Covid-19-cohort noted a strikingly pervasive transient regression of their symptoms (Giannetti 2021). Similarly “urticarial” or autistic persons seem protected (Brondino 2021). The at times leaky low ACE2-density (J Li 2007) “lymphatic cauldron”, MCs closely relate to, has received only marginal attention (Witte & Daley 2020).

Findings in severe Covid-19 point to a pivotal both protective and pathogenic (Rathore & St. John 2020) role of MCs (Tan 2021), which flavonoids might modulate (Theoharides 2020). MCs hereby, like in dengue-fever, parallel the overall response in being initially protective and then destructive by overactivation (Ricke 2021).

### **Interstitial clearance failure: SARS-CoV-2 attack the nasal ganglion**

While anosmia with rarer ageusia is (not neuro-specifically) pathognomonic for early Covid-19, all PASC-cases present ORL-pathology (Davis 2021). The battles from the beginning take place inside noses and nasopharyngeal lymphoid tissues (Gallo 2020) since SARS-2 attacks the nasal mucosa early and even intraneurally (Meinhardt 2021). Among ganglia in deer mice (Fagre 2020) mainly the PPG and trigeminal one were

SARS-2-antigen-positive (SAg2+) and attacked by neutrophils, as was the olfactory bulb; myeloid precursors were SAg2+ in the calvarial marrow – which is alimented through tubes from the meninges which allow MCs to determine calvarial bone and marrow in mice and men; (Cai 2019, Herisson 2020, Ogle 2004, Fong 2003, Dasgupta & Jeong 2019). Intranasally infected mice with humanized ACE2-receptors accordingly were SAg2+ in neurons, astrocytes, and microglia.

### **PASC/«LONG COVID-19»: SYNDROMATIC FATIGUE BEYOND BANALITY**

Weakly correlated with in-hospital hypoxia Covid-19 in 42% months after still slowed cognition - half struggling with verbal recall. Besides cerebral derangements, feared among the elderly (Krupp 2021), the lasting or subsequently appearing (20%) PASC (see Table 3) is related to: the lungs, “cardiovascular” chest-tightness or MC-related cardiopathies (Dixit 2021, Kounis 2021).

Various pathomechanisms play: 1.) non-healing lesions or effects via intruded virus, persisting in sanctuaries/“reservoirs”; 2.) PICKS-derived also immunometabolic “scars” and ongoing slight (immuno-)thrombotic(-embolic) events and cytokine imbalances in blood, lymphatics (Witte & Daley 2020) or interstitium; 3.) IHH-like imbalances connected with CSF dynamics; 4.) endocrinopathies; 5.) secondarily advantaged noxious pathogens (Proal & VanElzakker 2021), including 6.) such subverting immune cells from inside (Trevisanus 2020) or via dys-microbiosis (Rhoades 2021); 7.) coincidental or locally generated anti-cerebral autoimmunity; 8.) iatrogenic effects; 9.) subjective and objective psychosocial stresses, unhealthy life-styles and tertiary behaviors.

### **Vascular compliance explained: also against dysorthostasis in ME/CSF**

Besides post-infectious «sickness syndromes» (Kealy 2020) after microbial challenges, the “myalgic encephalomyelitis/chronic fatigue syndrome(s)” (ME/CFS) in 0.4% of humans constitutes a, meddled (Twisk 2018), first reference when listening to patients who, after variously severe COVID-19-infections, stay or become crushed by fatigue (Komaroff & Lipkin 2021) after slightest physical (or mental) efforts - topped by obligatory post-exertional malaise (PEM). Persons with this unrewardingly health-care-consuming condition involving ECs lack recognition from social insurances despite highly resistant persisting fatigue and (in 86%) intolerance of orthostasis (IO) - often even when sitting (van Campen 2020). After an often infectious trigger ME/CFS's day-long prodromes escalate into a bewildering array of (micro-macro)-abnormalities of moodiness, nausea, paraesthesia, or less often (head-)aches or rare gut problems (Ghali 2021) - pointing to a probable cephalic and not caudo-corporeal (possibly lymphatic) inflammatory source.

**Table 3.** Long COVID: Symptoms from international cohort over 7 months. Modified from: Davis HE (2021)

<b>"LONG COVID-19" / PASC: SEVERITY &amp; COURSE.</b>			
Modif. After: Davis (2021) Long COVID: international cohort over 7 months:			
<b>PASC</b>	<b>Slight / Initial</b>	<b>Moderate</b> > 6 months: Recovering	<b>Very/Severe (1:5)</b> Moderate (2:3) Persistent
Nr. symptoms	11 (max. week 2)	17 (max. week 8)	14 > week 28
<b>Main symptoms</b> 100%: any ORL >90% : Fatigue Vegetative Respiration Musculoskeletal Sensorimotor >80% : Gut Cardiovascular <b>PEM</b> - Post-Exertional (physical , mental) Malaise Mood Cognition >70% : Sleep Headache Memory <b>45 - &lt; 70%:</b> Reproduction / Hormones Skin, Smell & Taste <b>15 - 25%:</b> Attention Hair-loss Dyspnea Hallucinatory Auto-/Immune symptoms		<b>Worst problems</b>  <b>Fatigue</b> 78% ↘45% <b>PEM</b> (mental & physical) > 70% Breathing Cognitive 55%	<b>Worst problems</b> 86% ↗ under stress  Fatigue 87% Job: less 45% Job: none 22%. <b>PEM</b> (mental & physical) 72%  Breathing Cognitive <u>Antibodies:</u> Celiac, RA, rare ANA,
Cl.1: improving Diarrhea/Vomit. Slight ORL Fever	Cl.2-A: improving Nausea Smell & Taste POTS-like faints Respiration & ORL Aches / Chest	Cl.2-B: stable <b>Fatigue</b> , Head-Aches, Bones Sudden dizziness Sleep / Halluc. /Slurr. Covid-toe	Cl.3: deteriorating Brain fog Bladder Menstrual <b>PEM</b> Joints Neuralgia Motricity Memory Eye Hearing Tinnitus Reflux Constipation Speech Language Inflamed veins Rashes Derm.graphia <b>NEW</b> allergies
	Lymphatics?	MC: Kounis-syndrome MC: Takotsubo	Anti-Phospholipid Ab Anti-IFN- Antibodies
MCTC skin brain "connective" (lung) submucosal gut Tryptase (Chymase) Meningo-arterio- parenchymal MCs Nasal lamina prop.	Lung: ↘ IL-4 IL-13 C3a C5a complement-receptor MRGPRX2-receptor Long-living		<b>NEW</b> anaphylaxia IgE? Pseudo-Anaphylaxia ? <b>MRGPRX2-receptor</b> [Kumar 2021] (also Basophils)
MCT "mucosa" Lung alveola, gastric Tryptase-only Many brain MCs Nasal epithel	Lung: ↘ IL-5 IL-6 Not long-living		<b>NEW</b> anaphylaxia IgE? Vaccine anaphylaxia ? [0.03%]
Mast cells mature inside tissues where they exert a "rheostatic" function according to a not simply "connective" to "mucosal" spectrum. (Frossi 2017; Gurish & Austin 2012). After lung-Covid-19 conjoined celiac TG- or RA-related antibodies could be risk (Lingel 2021)			

Normal orthostasis induces immediate autoregulation of cerebrovascular vessel changing diameter (resistance) but also “compliance” by, quicker, distensibility (Brasard 2021) remaining moderately preserved in OI. Distensibility with constant diameter – also in the brain – remains mysterious without considering the hidden pervasive aortic blueprint of arteries and the resulting “Cerebral IntraMural Reverse Arterial Flow” (CIMURAF-model; Treviranus 2018, 2019, 2020) constantly pushing axially wrung coronal compartments bounded by “candy-cracker” twists (...) at the borders to relaxation (...) towards the extracranial arterio-lymphatic outlet. These chambers - moving under plausible peristaltic control from the checker-board-like PPG efferents by its stimulations – conceivably can be narrowed (pressurized) or distended (depressurized) following the narrowing or broadening of coronal zones of (radial, but mostly alternatingly sensed circumferential) muscular contractions - solving for the first time the riddle of “softness without distention” of more non-individual (Zamir 2007) “apparent vascular compliance” responding with impedances to pulsatile flow (Hu 2006, Moir 2020). The peristaltic steering in fact may well anticipate pulsatile peaks by some feed-forward reflex or axial ionic signaling. CIMURAF also explains (b.) the lower coronal than axial resistance explaining recent OI-findings (Finkelmeyer 2018): (c.) long-term parenchymal stiffening through interstitial clearance failure causing “interstitial fluidopathy” (Taoka & Naganawa 2021) and (d.) increases in CBF cooling consequential overheating – also resulting in an added radial pressurization of the arterial wall, conceivably hampering CIMURAF (transversing the media).

CIMURAF being plausibly steered by the PPG (Treviranus 2020) – given its efferents’ architecture and neurochemistry (Nizari 2021) – this implies a putative prime pathogenic role for PPG in Covid-19, since SARS-2 inflames and colonizes it. Considering that if CIMURAF is (mis-)directed by the invaded PPG in Covid-19, its disturbances – troubling a newly postulated role as vascular and/or interstitial compliance modulator – plausibly result both in fatigue-inducing brain inflammation after dysfunctions of the BBB (also by MCs unleashed by the PPG), and their strain by autoregulatory failures.

### **Idiopathic Intracranial Hypertension: choroid plexus, leptin, mast cells**

Headache and fatigue defining IIH are also frequent in ME/CFS as are cognitive troubles, low mood, dizziness, and aches. While the normal-sized choroid plexus in IIH harbor a treatable hypersecretion causing a quicker aquaeductal flow generating higher pulsatile peaks, they are surrounded by barrier-opening MCs (Zhuang 1996). IIH lessens with lowering of obese body weight, itself proportional to increased leptin, which is increased in IIH maybe by boosting choroideal ion transport (Alimajstorovic 2020). In COVID-19 such

adipokines decide on survival and leptin by immunometabolism also shifts MCs and Mφs towards vasculo-inflammatory modes (Żelechowska 2018) explaining the doubled cardio-vascular risk in IIH and possibly its tiring symptomatology because MC may permeabilize the choroid plexus (Turygi 2005).

### **MC and the PPG in Covid-19 (and ME/CSF)**

The extrinsic innervation to neurovascular units (NVU) fades out with the Virchow-Robin spaces (VRS). Its parasympathetic part stems mostly from the PPG, which is therapeutically stimulated to transiently open the BBB (Schmidt 2019). Only its cholinergic output to the cerebrovascular arteries, before approaching Willis' circle, from the internal ethmoid arteries in front, passes through a rete over the cribriforme plate (Norwood 2019, Hsu 2019), the ethmoid roof perforated by olfactory nerves being again accompanied by channels draining CSF (and cells) into the nasal lymphatics (Carare 2014, Hara & Weir 1986, Suzuki 1990b). This cribriforme plate lies in SARS-2' initial attack zone. Inhibition of PPG's efferent periarterial functions (e. g. CIMURAF, MC-inhibition) by the trigeminally-relayed Suzuki-afferents could explain why gingivitis (also by IL-27) increases Covid-19's severity 3.5-fold (Marouf 2021).

Although CIMURAF through the hidden “aortic blueprint” of all arteries first interpreted the cerebral intramural clearance by muscular force (Treviranus 2018, Aldea 2019) the analogous mechanisms for extracranial arteries has not been explicitly postulated. Similar neutrally driven torsional coronal chambers can be supposed to heavily influence the behavior of abluminal and adventitial MCs – also in the context of the core COVID-19 (micro-)thrombotic events.

### **MICROBIAL NICHES, BCG, AND THE ANCIENT SARS-2 – ORO-MYCOBACTERIAL OVERLAP**

SARS-2 enters microbial niches (Proal & Van Elzakker 2021) – possibly even by reactivating “free-loaders” or by hijacking already subverted myeloid cells e. g. by ingenious mycobacteria (Treviranus 2019). In latent or acute TBC – the normal daily killer at pandemic's levels – low whole-blood-plasma INF- $\gamma$  responses to SARS-2-spike-protein by shared gene expression revealed overlapping hypo-immunity (Petroni 2021) among circulating myeloid subpopulations: IFN- $\gamma$  and TNF- $\alpha$  were increased in both active TBC and Covid-19 and lacking in latent TBC or Influenza (Sheerin 2020). If this should extend to parts of the “oral mycobiome” it might explain the gingival SARS-2-sanctuary and periodontitis is a risk factor for infection and severe Covid-19.

Crude epidemiology corroborates the miracle BCG as a means to revert the Warburg-effect - providing ready-made intermediary products for rapid synthesis (at high cost) - interacting with Covid-19 mortality.



BCG-proteomics revealed MCH-I-restricted epitopes made of short very primordial conserved sequences overlapping exceptionally between SARS-2-epitopes which both T-cells and B-cells target (Urbán 2020).

## CONCLUSIONS AND OUTLOOK

The PASC resembling unresolving SARS-cases at the moment of writing looms as an undecided prediction. Unexplored remains the role of neural or direct openings of the “lymphatic cauldron”. Such unresolving – often microbial – challenges presenting with a huge variety of responses - beyond the pervasive roles for mast cells (as also sequentially “etosis-practicing” trespassers across sane brain barriers) appear also to be rooted in the here proposed new pathophysiological models for a.) orthostatically focussed chronic fatigue and b.) intracranial hypertension. Covid-19 by starting at the nasal entry with a 1<sup>st</sup>-attack on the social-stress- and facially-sensitive nasal ganglion mis-directs the cerebral arterial intramural clearance normally offering pulse-anticipating minute “compliance” by varying the width of wrung sliding chambers. Mental health rehabilitation starts with advocating a new soft-neurological-psychiatric liaison. Wether BCG or future vaccines training the innate system (e.g. against anxio-depression) will help in this remains to be seen.

**Acknowledgements:** None.

**Conflict of interest:** None to declare.

## References

1. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F et al.: Pulmonary Vascular Endothelialitis, Thrombosis, and angiogenesis in Covid-19. *N Engl J Med* 2020; 383:120-28
2. Adhanom Ghebreyesus T: Addressing mental health needs: an integral part of COVID-19 response. *World Psychiatry* 2020; 19:129-30
3. Aldea R, Weller RO, Wilcock DM, Carare RO, Richardson G: Cerebrovascular smooth muscle cells As the drivers of intramural periarterial drainage of the brain. *Front Aging Neurosci* 2019; 11: 1
4. Alhatem A, Spruijt O, Heller DS, Chokshi RJ, Schwartz RA, Lambert WC: “Do-Not-Resuscitate (DNR)” status determines mortality in patients with COVID-19. *Clin Dermatol* 2020 Nov 28
5. Alimajstorovic Z, Westgate CSJ, Jensen RH, Eftekhari S, Mitchell J, Vijay Vet al.: Guide to preclinical models used to study the pathophysiology of idiopathic intracranial hypertension. *Eye (Lond)* 2020; 34:1321-33
6. Apolone G, Montomoli E, Manenti A, Boeri M, Sabia F, Hyseni I et al.: Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy. *Tumori* 2020; 11:300891620974755
7. Arcuri C, Mecca C, Giambanco I, Donato R: Parenchymal and non-parenchymal immune cells in the brain: A critical role in regulating CNS functions. *Int J Dev Neurosci* 2019; 77:26-38
8. Badraoui R, Alrashedi MM, El-May MV, Bardakci F: Acute respiratory distress syndrome: a life threatening associated complication of SARS-CoV-2 infection inducing COVID-19. *J Biomol Struct Dyn* 2020; 1-10
9. Banks WA, Kastin AJ, Durham DA: Bidirectional transport of interleukin-1alpha across the blood-brain barrier. *Brain Res Bull* 1989; 23:433-7
10. Bayati A, Kumar R, Francis V, McPherson PS: SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis. *J Biol Chem* 2021; 296:100306
11. Boden M, Cohen N, Froelich JM, Hoggatt KJ, Abdel Magid HS, Mushiana SS: Mental disorder prevalence among populations impacted by coronavirus pandemics: A multilevel meta-analytic study of COVID-19, MERS & SARS. *Gen Hosp Psychiatry* 2021; 70:124-33
12. Bonaventura A, Vecchié A, Dagna L, Martinod K, Dixon DL, Van Tassell BW et al.: Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. *Nat Rev Immunol* 2021; 21:319-29
13. Boneau RH, Padgett DA, Sheridan JF: Twenty years of psychoneuroimmunology and viral infections in Brain, Behavior, and Immunity. *Brain Behav Immun* 2007; 21:273-80
14. Brassard P, Labrecque L, Smirl JD, Tymko MM, Caldwell HG, Hoiland RL et al.: Losing the dogmatic view of cerebral autoregulation. *Physiol Rep* 2021; 9:e14982
15. Brondino N, Bertoglio F, Forneris F, Faravelli S, Borghesi A, Damiani S et al.: A pilot study on Covid and autism: Prevalence, clinical presentation and vaccine side effects. *Brain Sci* 2021; 11:860
16. Brown MA & Hatfield JK: Mast cells are important modifiers of autoimmune disease: With so much evidence, why is there still controversy? *Front Immunol* 2012; 3:147
17. Bryant-Genevier J, Rao CY, Lopes-Cardozo B, Kone A, Rose C, Thomas I, et al.: Symptoms of depression, anxiety, post-traumatic stress disorder, and suicidal ideation among state, tribal, local, and territorial public health workers during the COVID-19 pandemic - United States, March-April 2021. *MMWR Morb Mortal Wkly Rep* 2021; 70:947-52
18. Butler N, Pewe L, Trandem K, Perlman S: Murine encephalitis caused by HCoV-OC43, A human coronavirus with broad species specificity, is partly immune-mediated. *Virology* 2006; 347:410-21
19. Butovt R, Meunier N, Bryche B, von Bartheld CS: The olfactory nerve is not a likely route to brain infection in COVID-19: A critical review of data from humans and animal models. *Acta Neuropathol* 2021; 141:809-22
20. Cai R, Pan C, Ghasemigharagoz A, Todorov MI, Förstera B, Zhao S et al.: Panoptic imaging of transparent mice reveals whole-body neuronal projections and skull-meninges connections. *Nat Neurosci* 2019; 22:317-27
21. Callahan V, Hawks S, Crawford MA, Lehman CW, Morrison HA, Ivester HM et al.: The pro-inflammatory chemokines CXCL9, CXCL10 and CXCL11 are upregulated following SARS-CoV-2 infection in an AKT-dependent manner. *Viruses* 2021; 13:1062
22. Capuron L, Miller AH: Immune system to brain signaling: Neuropsychopharmacological implications. *Pharmacol Ther* 2011; 130:226-38
23. Carare CO, Hawkes CA, Weller RO: Afferent and efferent immunological pathways of the brain. *Anatomy, function and failure. Behavior Brain Immunity* 2014; 36:9-14

24. Carrouel F, Gonçalves LS, Conte MP, Campus G, Fisher J, Fraticelli L et al.: Antiviral activity of reagents in mouth rinses against SARS-CoV-2. *J Dent Res* 2021; 100:124-32
25. Casesmeiro Roger J: By investigating itself the US can answer many of the key COVID19 origin questions (26th may 2021) [www.independentsciencenews.org/]
26. Cataldi M, Pignataro G, Tagliatalata M: Neurobiology of coronaviruses: Potential relevance for COVID-19 2020. *Neurobiology of Disease* 2020; 143:105007
27. CDC (Center for Disease Control): Human Coronavirus types [www.cdc.gov/coronavirus/types.html]
28. Chan YH, Fong SW, Poh CM, Carissimo G, Yeo NK, Amrun SN et al.: Asymptomatic COVID-19: disease tolerance with efficient anti-viral immunity against SARS-CoV-2. *EMBO Mol Med* 2021; 13:e14045
29. Cheng Q, Yang Y, Gao J: Infectivity of human coronavirus in the brain. *EBioMedicine* 2020; 56:102799
30. Chossegros P: L'épidémie de COVID-19: une autre histoire pourrait être racontée. *Presse Med Form* 2020; 1:447-50
31. Cyranoski D: Inside the Chinese lab poised to study world's most dangerous pathogens. *Nature* 2017; 542:399-400
32. Cyranoski D: The biggest mystery: what it will take to trace the coronavirus source. *Nature* 2020 Jun 5
33. Dasgupta K & Jeong J: Developmental biology of the meninges. *Genesis* 2019; 57:e23288
34. Davies K, Buczkowski H, Welch SR, Green N, Mawer D, Woodford N et al.: Effective in vitro inactivation of SARS-CoV-2 by commercially available mouthwashes. *J Gen Virol* 2021; 102:001578
35. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y et al.: Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine* 2021; 101019. [www.thelancet.com/cms/10.1016/j.eclim.2021.101019/attachment/9ba05d3c-2ac1-47f1-a992-f9819402aa10/mmcl.docx]
36. Desforges M, Le Coupance A, Dubeau P, Bourgouin A, Lajoie L, Dubé M et al.: Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? *Viruses* 2019; 12:14
37. Dixit NM, Churchill A, Nsair A, Hsu JJ: Post-acute COVID-19 syndrome and the cardiovascular system: What is known? *Am Heart J Plus* 2021; 5:100025
38. Dong F, Liu HL, Dai N, Yang M, Liu JP: A living systematic review of the psychological problems in people suffering from COVID-19. *J Affect Disord* 2021; 292:172-88
39. Dubé M, Le Coupance A, Wong AHM, Rini JM, Desforges M, Talbot PJ: Axonal transport enables neuron-to-neuron propagation of human coronavirus OC43. *J Virol* 2018; 92:e00404-18
40. Ellis P, Somogyvári F, Virok DP, Nosedá M, McLean GR: Decoding Covid-19 with the SARS-CoV-2 genome. *Curr Genet Med Rep* 2021; 9:1-12
41. Erickson MA & Banks WA: Age-associated Changes in the Immune System and blood-brain barrier Functions. *Int J Mol Sci* 2019; 20:1632
42. Erickson MA & Banks WA: Neuroimmune axes of the blood-brain barriers and blood-brain Interfaces: Bases for physiological regulation, disease States, and pharmacological interventions. *Pharmacol Rev* 2018; 70:278-314
43. Erickson MA, Rhea EM, Knopp RC, Banks WA: Interactions of SARS-CoV-2 with the blood-brain barrier. *Int J Mol Sci* 2021; 22:2681
44. Ermis U, Rust MI, Bungenberg J, Costa A, Dreher M, Balfanz P, et al.: Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients. *Neurol Res Pract* 2021; 3:17
45. Fagre A, Lewis J, Eckley M, Zhan S, Rocha SM, Sexton NR et al.: SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for spillback to New World rodents. *PLoS Pathog.* 2021; 17:e1009585
46. Fahmy OH, Daas FM, Salunkhe V, Petrey JL, Cosar EF, Ramirez J, Akca O: Is microthrombosis the main pathology in coronavirus disease 2019 severity? - A systematic review of the postmortem pathologic findings. *Crit Care Explor* 2021; 3:e0427
47. Finkelmeyer A, He J, Maclachlan L, Blamire AM, Newton JL: Intracranial compliance is associated with symptoms of orthostatic intolerance in chronic fatigue syndrome. *PLoS One* 2018; 13:e0200068
48. Fong KD, Warren SM, Lobo EG, Henderson JH, Fang TD, Cowan CM et al.: Mechanical strain affects dura mater biological processes: implications for immature calvarial healing. *Plast Reconstr Surg* 2003; 112:1312-27
49. Fongaro G, Stoco PH, Souza DSM, Grisard EC, Magri ME, Rogovski P, et al.: The presence of SARS-CoV-2 RNA in human sewage in Santa Catarina, Brazil, November 2019. *Sci Total Environ* 2021; 778:146198
50. Frossi B, Mion F, Tripodo C, Colombo MP, Pucillo CE: Rheostatic functions of mast cells in the control of innate and adaptive immune responses. *Trends Immunol* 2017; 38:648-56
51. Gallo O, Locatello LG, Mazzoni A, Novelli L, Annunziato F: The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. *Mucosal Immunol* 2021; 14:305-16
52. Gebremeskel S, Schanin J, Coyle KM, Butuci M, Luu T, Brock EC et al.: Mast cell and eosinophil activation are associated with COVID-19 and TLR-mediated viral inflammation: Implications for an anti-Siglec-8 antibody. *Front Immunol* 2021; 12:650331
53. Generoso JS, Barichello de Quevedo JL, Cattani M, Lodetti BF, Sousa L, Collodel A et al.: Neurobiology of COVID-19: how can the virus affect the brain? *Braz J Psychiatry* 2021; PMID:33605367
54. Ghali A, Lacout C, Ghali M, Gury A, Delattre E, Lavigne C, Urbanski G: Warning signals of post-exertional malaise in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A retrospective analysis of 197 patients. *J Clin Med* 2021; 10:2517
55. Giannetti MP, Weller E, Alvarez-Twose I, Torrado I, Bonadonna P, Zanotti R, et al.: COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms. *J Allergy Clin Immunol Pract* 2021; 9:2083-6
56. Gramaglia C, Gambaro E, Bellan M, Balbo PE, Baricich A, Sainaghi PP et al. & NO-MORE COVID Group: Mid-term psychiatric outcomes of patients recovered from COVID-19 from an Italian cohort of hospitalized patients. *Front Psychiatry* 2020; 12:667385
57. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y et al.: Multiple organ infection and the pathogenesis of SARS. *J Exp Med* 2005; 202:415-24
58. Guimbal S, Cornuault L, Rouault P, Hollier PL, Chapouly C, Bats ML et al.: Mast cells are the trigger of small vessel disease and diastolic dysfunction in diabetic obese mice. *Arterioscler Thromb Vasc Biol* 2021; 41:e193-e207

59. Gupta M & Weaver DF: COVID-19 as a trigger of brain autoimmunity. *ACS Chem Neurosci* 2021; 12:2558-61
60. Gurish MF & Austen KF: Developmental origin and functional specialization of mast cell subsets. *Immunity* 2012; 37:25-33
61. Han Y, Li Y, Jiang Y: The prognostic value of plasma MicroRNA-155 and MicroRNA-146a level in severe sepsis and sepsis-induced acute lung injury patients. *Clinical Laboratory* 2016; 62:2355-60
62. Hara H & Weir B: Pathway of Acetylcholinesterase containing nerves to the major cerebral Arteries in rats. *J Comp Neurol* 1986; 250:245-52
63. Haslak F, Barut K, Durak C, Aliyeva A, Yildiz M, Guliyeva Vet al.: Clinical features and outcomes of 76 patients with COVID-19-related multi-system inflammatory syndrome in children. *Clin Rheumatol* 2021; 1-12
64. Herisson F, Frodermann V, Courties G, Rohde D, Sun Y, Vandoorne K et al.: Direct vascular channels connect skull bone marrow and the brain surface enabling myeloid cell migration. *Nat Neurosci* 2018; 21:1209-17
65. Hernández-Fernández F, Sandoval Valencia H, Barbella-Aponte RA, Collado-Jiménez R, Ayo-Martín Ó, Barrera C et al.: Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. *Brain* 2020; 143:3089-103
66. Himmerich H, Patsalos O, Lichtblau N, Ibrahim MAA, Dalton B: Cytokine research in depression: Principles, challenges, and open questions. *Front Psychiatry* 2019; 10:30
67. Howard J, Huang A, Li Z, Tufekci Z, Zdimal V, van der Westhuizen HM et al.: An evidence review of face masks against COVID-19. *Proc Natl Acad Sci U S A* 2021; 118:e2014564118
68. Hsu M, Rayasam A, Kijak JA, Choi YH, Harding JS, Marcus SA, Karpus WJ, Sandor M, Fabry Z: Neuroinflammation-induced lymphangiogenesis near the cribriform plate contributes to drainage of CNS-derived antigens and immune cells. *Nat Commun* 2019; 10:229
69. Hu X, Alwan AA, Rubinstein EH, Bergsneider M: Reduction of compartment compliance increases venous flow pulsatility and lowers apparent vascular compliance: implications for cerebral blood flow hemodynamics. *Med Eng Phys* 2006; 28:304-14
70. Hu B, Zeng LP, Yang XL, Ge XY, Zhang W et al.: Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. *PLOS Pathogens* 2017; 13:e1006698
71. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395:497-506
72. ISARIC Clinical Characterisation Group: COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. *Infection* 2021; 25:1-17
73. Kalra SS, Jaber J, Alzghoul BN, Hyde R, Parikh S, Urbine D, Reddy R: Pre-existing psychiatric illness is associated with an increased risk of delirium in patients with acute respiratory distress syndrome. *J Intensive Care Med* 2021; 8850666211019009
74. Kealy J, Murray C, Griffin EW, Lopez-Rodriguez AB, Healy D, Tortorelli LS, et al.: Acute inflammation alters brain energy metabolism in mice and humans: role in suppressed spontaneous activity, impaired cognition, and delirium. *J Neurosci* 2020; 40:5681-96
75. Komaroff AL & Lipkin WI: Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. *Trends Mol Med* 2021
76. Komi EAD, Kuebler WM: Significance of mast cell formed extracellular traps in microbial defense. *Clin Rev Allergy Immunol* 2021; 22:1-20
77. Kounis NG, Koniari I, de Gregorio C: COVID-19 and Kounis Syndrome: Deciphering their relationship. *Balkan Med J* 2021; 38:145-9. doi:10.5152/balkanmedj.2021.21097
78. Kramer J: What you need to know about the COVID-19 lab-leak hypothesis. *National Geographic*. 04.06.2021. [<https://www.nationalgeographic.com/science/article/what-you-need-to-know-about-the-covid-19-lab-leak-hypothesis/>]
79. Krupp K, Madhivanan P, Killgore WDS, Ruiz JM, Carvajal S, Coull BM, Grandner MA: Neurological manifestations in COVID-19: An unrecognized crisis in our elderly? *Adv Geriatr Med Res* 2021; 3:e210013
80. Kumar M, Duraisamy K, Chow BK: Unlocking the non-IgE-mediated pseudo-allergic reaction puzzle with Mas-Related G-Protein Coupled Receptor Member X2 (MRGPRX2). *Cells* 2021; 10:1033
81. Kunder CA, St John AL, Abraham SN: Mast cell modulation of the vascular and lymphatic endothelium. *Blood* 2011; 118:5383-93
82. Kunder CA, St John AL, Li G, Leong KW, Berwin B, Staats HF, Abraham SN: Mast cell-derived particles deliver peripheral signals to remote lymph nodes. *J Exp Med* 2009; 206:2455-67
83. La Rosa G, Mancini P, Bonanno Ferraro G, Veneri C, Iaconelli M, Bonadonna L, Lucentini L, Suffredini E: SARS-CoV-2 has been circulating in northern Italy since December 2019: Evidence from environmental monitoring. *Sci Total Environ* 2021; 750:141711
84. Lee E, Eo JC, Lee C, Yu JW: Distinct features of brain-resident macrophages: Microglia and non-parenchymal brain macrophages. *Mol Cells* 2021; 44:281-91
85. Lee S, Kang BM, Kim JH, Min J, Kim HS, Ryu H et al.: Real-time in vivo two-photon imaging study reveals decreased cerebro-vascular volume and increased blood-brain barrier permeability in chronically stressed mice. *Sci Rep* 2018; 8:13064
86. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G: Assessing the Age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. *Eur J Epidemiol* 2020; 35:1123-38
87. Li F, Wang Y, Lin L, Wang J, Xiao H, Li J et al.: Mast cell-derived exosomes promote Th2 cell differentiation via OX40L-OX40 ligation. *J Immunol Res* 2016; 2016:3623898
88. Li J, Gao J, Xu YP, Zhou TL, Jin YY, Lou JN: [Expression of severe acute respiratory syndrome coronavirus receptors, ACE2 and CD209L in different organ derived microvascular endothelial cells]. *Zhonghua Yi Xue Za Zhi* 2007; 87:833-7 (Chin.)
89. Lingel H, Meltendorf S, Billing U, Thurm C, Vogel K, Majer C, et al.: Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals. *J Autoimmun* 2021; 122:102682. doi:10.1016/j.jaut.2021.102682
90. Lins B: Maternal immune activation as a risk factor for psychiatric illness in the context of the SARS-CoV-2 pandemic. *Brain Behav Immun Health* 2021; 16:100297

91. Liu C, Pan W, Li L, Li B, Ren Y, Ma X: Prevalence of depression, anxiety, and insomnia symptoms among patients with COVID-19: A meta-analysis of quality effects model. *J Psychosom Res* 2021; 147:110516
92. Lo TC, Chen YY: Ocular and systemic manifestations in paediatric Multisystem Inflammatory Syndrome associated with COVID-19. *J Clin Med* 2021; 10:2953
93. Lu Y, Li X, Geng D, Mei N, Wu PY, Huang CC et al.: Cerebral micro-structural changes in COVID-19 patients - An MRI-based 3-month follow-up Study. *EclinicalMedicine* 2020; 25:100484
94. Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M et al.: Longitudinal analyses reveal immunological misfiring in severe COVID-19. *Nature* 2020; 584:463-9
95. Lynas M: *Our Final Warning: Six Degrees of Climate Emergency*. 4th Estate: London, UK, 2020
96. Maier SF, Goehler LE, Fleshner M, Watkins LR: The role of the vagus nerve in cytokine-to-brain communication. *Ann N Y Acad Sci* 1998; 840:289-300
97. Mantri CK & St John AL: Immune synapses between mast cells and  $\gamma\delta$  T cells limit viral infection. *J Clin Invest* 2019; 129:1094-108
98. Marouf N, Cai W, Said KN, Daas H, Diab H, Chinta VR, Hassain AA, Nicolau B, Sanz M, Tamimi F: Association between periodontitis and severity of COVID-19 infection: A case-control study. *J Clin Periodontol* 2021; 48:483-91
99. Matschke J, Lütgehetmann M, Hagel C, Sperhake JP, Schröder AS, Edler C et al.: Neuropathology of patients with COVID-19 in Germany: A post-mortem case series. *Lancet Neurol* 2020; 19:919-29
100. Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R et al.: Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. *Nat Neurosci* 2021; 24:168-75. doi:10.1038/s41593-020-00758-5
101. Meng-Li Wu, Feng-Liang Liu, Jing Sun, Xin Li, Xiao-Yan He, Hong-Yi Zheng et al.: SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury. *bioRxiv Jun 2021*
102. Méry G, Epaulard O, Borel AL, Toussaint B, Le Gouellec A: COVID-19: Underlying adipokine storm and angiotensin 1-7 umbrella. *Front Immunol* 2020; 11:1714
103. Moir ME, Klassen SA, Zamir M, Shoemaker JK.: Rapid changes in vascular compliance contribute to cerebrovascular adjustments during transient reductions in blood pressure in young, healthy adults. *J Appl Physiol [1985]* 2020; 129:27-35
104. Morgello S: Coronaviruses and the central nervous system. *J Neurovirol* 2020; 26:459-73
105. Morrison J, Rathore APS, Mantri CK, Aman SAB, Nishida A, St John AL: Transcriptional profiling confirms the therapeutic effects of mast cell stabilization in a dengue disease model. *J Virol* 2017; 91:e00617-17
106. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS et al.: Post-acute COVID-19 syndrome. *Nat Med* 2021; 27:601-15
107. Nikitina E, Larionova I, Choinzonov E, Kzhyshkowska J: Monocytes and macrophages as viral targets and reservoirs. *Int J Mol Sci* 2018; 19:2821
108. Nizari S, Wells JA, Carare RO, Romero IA, Hawkes CA: Loss of cholinergic innervation differentially affects eNOS-mediated blood flow, drainage of A $\beta$  and cerebral amyloid angiopathy in the cortex and hippocampus of adult mice. *Acta Neuropathol Commun* 2021; 9:12
109. Norwood JN, Zhang Q, Card D, Craine A, Ryan TM, Drew PJ: Anatomical basis and physiological role of cerebrospinal fluid transport through the murine cribriform plate. *Elife* 2019; 8:e44278
110. Ogle RC, Tholpady SS, McGlynn KA, Ogle RA: Regulation of cranial suture morphogenesis. *Cells Tissues Organs* 2004; 176:54-66
111. Oliver G, Kipnis J, Randolph GJ, Harvey NL: The lymphatic vasculature in the 21st century: Novel functional roles in homeostasis and disease. *Cell* 2020; 182:270-96
112. Outh R, Boutin C, Gueudet P, Suzuki M, Saada M, Aumaître H: Eosinopenia <100/ $\mu$ L as a marker of active COVID-19: An observational prospective study. *J Microbiol Immunol Infect* 2021; 54:61-8
113. Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednický Jet al.: Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). *J Med Virol* 2020; 92:699-702
114. Pellegrini L, Albecka A, Mallery DL, Kellner MJ, Paul D, Carter AP et al.: SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF barrier in human brain organoids. *Cell Stem Cell* 2020; 27:951-61.e5
115. Pelletier JS, Tessema B, Frank S, Westover JB, Brown SM, Capriotti JA: Efficacy of Povidone-iodine nasal and oral antiseptic preparations against severe SARS-CoV-2. *Ear Nose Throat J* 2021; 100(S2):192S-6S
116. Pertiwi KR, de Boer OJ, Mackaaij C, Pabittei DR, de Winter RJ, Li X, van der Wal AC: Extracellular traps derived from macrophages, mast cells, eosinophils and neutrophils are generated in a time-dependent manner during atherothrombosis. *J Pathol* 2019; 247:505-12
117. Peters EMJ, Schedlowski M, Watzl C, Gimsa U: To stress or not to stress: Brain-behavior-immune interaction may weaken or promote the immune response to SARS-CoV-2. *Neurobiol Stress* 2021; 14:100296
118. Petersen OH, Gerasimenko OV, Gerasimenko JV: Endocytic uptake of SARS-CoV-2: the critical roles of pH, Ca<sup>2+</sup> and NAADP. *Function (Oxf)* 2020; zqaa003
119. Petrone L, Petruccioli E, Vanini V, Cuzzi G, Gualano G, Vittozzi P et al.: Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2. *Int J Infect Dis* 2021; S1201-9712:00176-4
120. Plaze M, Attali D, Petit AC, Blatzer M, Simon-Loriere E, Vinckier F et al.: Repurposing chlorpromazine to treat COVID-19: The reCoVery study. *Encephale* 2020; 46:169-72
121. Portales-Cervantes L, Dawod B, Marshall JS: Mast cells and natural killer cells: A potentially critical interaction. *Viruses* 2019; 11:514
122. Proal AD & VanElzakker MB: Long COVID or Post-acute Sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. *Front Microbiol* 2021; 12:698169
123. Purja S, Shin H, Lee JY, Kim E: Is loss of smell an early predictor of COVID-19 severity: a systematic review and meta-analysis. *Arch Pharm Res*. 2021; 44:725-40
124. Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YSet al.: SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. *Infez Med* 2020; 28:74-84
125. Rapoport SI: Osmotic opening of the blood-brain barrier: Principles, mechanism, and therapeutic applications. *Cell Mol Neurobiol* 2000; 20:217-30
126. Rathore AP & St John AL: Protective and pathogenic roles for mast cells during viral infections. *Curr Opin Immunol* 2020; 66:74-81

127. Rimmelink M, De Mendonça R, D'Haene N, De Clercq S, Verocq C, Lebrun L et al.: Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. *Crit Care* 2020; 24:495
128. Ren S, Wang Y, Yue F, Cheng X, Dang R, Qiao Q et al.: The paraventricular thalamus is a critical thalamic area for wakefulness. *Science* 2018; 362:429-34
129. Reynolds JL & Mahajan SD: SARS-CoV2 alters blood brain barrier integrity contributing to neuro-inflammation. *J Neuroimmune Pharmacol* 2021; 16:4-6
130. Rhoades NS, Pinski A, Monsibais AN et al.: Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including *Pseudomonas aeruginosa*. *bioRxiv*. doi:1101/2021.05.20.445008
131. Rhoads DD & Pinsky BA: The truth about SARS-CoV-2 cycle threshold values is rarely pure and never simple. *Clin Chem* 2021; hvab146
132. Ricke DO, Gherlone N, Fremont-Smith P, Tisdall P, Fremont-Smith M: Kawasaki disease, multisystem inflammatory syndrome in children: antibody-induced mast cell activation hypothesis. *J Pediatrics Pediatr Med* 2020; 4:1-7
133. Ricke DO: Two different Antibody-Dependent Enhancement (ADE) risks for SARS-CoV-2 antibodies. *Front Immunol* 2021; 12:640093
134. Ripple WJ, Wolf C, Newsome TM, Barnard P, Moomaw WR, 11,258 scientists: World Scientists' Warning of a Climate Emergency. *BioScience* 2020; 70:8-12
135. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P et al.: Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. *Lancet Psychiatry* 2020; 7:611-27
136. Rogers JP, Watson CJ, Badenoch J, Cross B, Butler M, Song J et al.: Neurology and neuropsychiatry of COVID-19: A systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives. *J Neurol Neurosurg Psychiatry* 2021; 3:jnnp-2021-326405
137. Roszkowski M & Bohacek J: Stress does not increase blood-brain barrier permeability in mice. *J Cereb Blood Flow Metab* 2016;36:1304-15
138. Salazar de Pablo G, Vaquerizo-Serrano J, Catalan A, Arango C, Moreno C, Ferre F et al.: Impact of coronavirus syndromes on physical and mental health of health care workers: Systematic review and meta-analysis. *J Affect Disord* 2020; 275:48-57
139. Savoy SKA & Boudreau JE: The evolutionary arms race between virus and NK cells: Diversity enables population-level virus control. *Viruses* 2019; 11:959
140. Schmidt RF, Theofanis TN, Lang MJ, Stricsek GP, Lin R, Lebrun A et al.: Sphenopalatine ganglion stimulation is a reversible and frequency-dependent modulator of the blood-brain barrier. *Brain Res* 2019; 1718:231-41
141. Segreto R & Deigin Y: The genetic structure of SARS-CoV-2 does not rule out a laboratory origin: SARS-CoV-2 chimeric structure and furin cleavage site might be the result of genetic manipulation. *Bioessays* 2021; 43:e2000240. doi:10.1002/bies.202000240
142. Selye H: *The mast cells*. Butterworth Inc, Washington, DC, 1965
143. Sheerin D, Abhimanyu, Wang X, Johnson WE, Coussens A: Systematic evaluation of transcriptomic disease risk and diagnostic biomarker overlap between COVID-19 and tuberculosis: A patient-level meta-analysis. *medRxiv [Preprint]* 2020; 2020.11.25.20236646. doi:10.1101/2020.11.25.202
144. Shewale JG & Ratcliff JL: Overinterpretation of the antiviral results for human coronavirus strain 229E (HCoV-229E) relative to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). *J Med Virol* 2021; 93:1900-02
145. Si F, Wu Y, Wang X, Gao F, Yang D, Liu R, Yi Q: The relationship between Interleukin-27 gene polymorphisms and Kawasaki disease in a population of Chinese children. *Cardiol Young* 2018; 28:1123-8
146. Silver R & Curley JP: Mast cells on the mind: new insights and opportunities. *Trends Neurosci* 2013; 36:513-21
147. Silverman AJ, Sutherland AK, Wilhelm M, Silver R: Mast cells migrate from blood to brain. *J Neurosci* 2000; 20:401-8
148. Springer J, Zhang M, Funk R, Tawfik O, Ohno N, Miura N et al.: THU0506 Mast cell deficiency amplifies inflammatory response in a mouse model of Kawasaki disease. *Ann Europ Congr Rheumatol, EULAR 2019, Madrid, 12-15 June 2019*. [[https://ard.bmj.com/content/78/Suppl\\_2/542.2](https://ard.bmj.com/content/78/Suppl_2/542.2)]
149. Sutton L, Goodacre S, Thomas B, Connelly S: Do not attempt cardiopulmonary resuscitation (DNACPR) decisions in people admitted with suspected COVID-19: secondary analysis of the PRIEST observational cohort study. *Resuscitation* 2021; 164:130-8
150. Suzuki N, Hardebo JE, Kährström J, Owman C: Nerve fibers originating from the sphenopalatine ganglion enhances cortical blood flow in the rat. *J Cereb Blood Flow Metab* 1990; 10:383-91
151. Szcześniak D, Gładka A, Misiak B, Cyran A, Rymaszewska J: The SARS-CoV-2 and mental health: From biological mechanisms to social consequences. *Prog Neuropsychopharmacol Biol Psychiatry* 2021; 104:110046
152. Tan J, Anderson DE, Rathore APS, O'Neill A, Mantri CK, Saron WAA et al.: Signatures of mast cell activation are associated with severe COVID-19. *medRxiv* 2021; 2021.05.31.21255594
153. Taoka T, Naganawa S: Imaging for central nervous system (CNS) interstitial fluidopathy: disorders with impaired interstitial fluid dynamics. *Jpn J Radiol* 2021; 39:1-14
154. Theoharides TC & Conti P: COVID-19 and Multisystem Inflammatory Syndrome, or is it Mast Cell Activation Syndrome? *J Biol Regul Homeost Agents* 2020; 34:1633-6
155. Theoharides TC & Zhang B: Neuro-inflammation, blood-brain barrier, seizures and autism. *J Neuroinflammation* 2011; 8:168
156. Theoharides TC: COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. *Bio Factors* 2020; 1-3
157. Theoharides TC: Mast cells: the immune gate to the brain. *Life Sci* 1990; 46:607-17
158. Tong DM, Zhou YT, Wang YW: COVID-19-Associated acute brain dysfunction related to sepsis. *J Clin Med Res* 2021; 13:82-91
159. Traina G: Mast cells in the brain - Old cells, new target. *J Integr Neurosci* 2017; 16(S1):S69-S83
160. Treviranus GRS: Rescue of the appropriate "Thought-Action-Mood" space: Anatomy and mast cells generate «mixable» dimensions in language and statistics. *Psychiatr Danub* 2018; 30(Suppl. 7):S620-9. [[www.researchgate.net/publication/328830004](http://www.researchgate.net/publication/328830004)]

161. Treviranus GRS: Mast cell autocrinicity near cerebral arterial wall "reverse glymphatic flow" as prime target of electromagnetic effects. *Psychiatr Danub* 2019; 31(Suppl. 3):S357-70. [www.researchgate.net/publication/336776494]
162. Treviranus GRS: Psychoses by attacks from subverted mast cells: A role for arterial intramural flow badly steered by the nasal ganglia? *Psychiatr Danub* 2020; 32(Suppl. 1):S93-104. PMID:32890371. [www.researchgate.net/publication/344132860]
163. Turygin VV, Babik TM, Boyakov AA: Characteristics of mast cells in the choroid plexus of the ventricles of the human brain in aging. *Neurosci Behav Physiol* 2005; 35:909-11. doi:10.1007/s11055-005-0144-8
164. Twisk F: Myalgic Encephalomyelitis or What? The International Consensus Criteria. *Diagnostics (Basel)* 2018; 9:1
165. Urbán S, Paragi G, Burián K, McLean GR, Virok DP: Identification of similar epitopes between severe Acute respiratory syndrome coronavirus-2 and Bacillus Calmette-Guérin: potential for cross-reactive Adaptive immunity. *Clin Transl Immunology* 2020; 9:e1227
166. van Campen CLMC, Rowe PC, Visser FC: Cerebral blood flow is reduced in severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients during mild orthostatic stress testing: An exploratory study at 20 degrees of head-pp tilt testing. *Healthcare (Basel)* 2020; 13:169
167. Veglia F, Sanseviero E, Gabrilovich DI: Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. *Nat Rev Immunol* 2021; 21:485-98
168. Vukman KV, Ferencz A, Fehér D, Juhos K, Lőrincz P, Visnovitz T et al.: An implanted device enables in vivo monitoring of extracellular vesicle-mediated spread of pro-inflammatory mast cell response in mice. *J Extracell Vesicles* 2020; 10:e12023
169. Walker AK, Kavelaars A, Heijnen CJ, Dantzer R: Neuroinflammation and comorbidity of pain and depression. *Pharmacol Rev* 2013; 66:80-101
170. Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q et al.: Molecular mechanism for Antibody-Dependent Enhancement of coronavirus entry. *J Virol* 2020; 94:e 02015-19
171. Watkins LR, Maier SF, Goehler LE: Cytokine-to-brain communication: A review & analysis of alternative mechanisms. *Life Sci* 1995; 57:1011-26
172. Weiss S, Yitzhaki S, Shapira SC: Lessons to be learned from recent biosafety incidents in the United States. *Isr Med Assoc J* 2015; 17:269-73
173. Wertheim JO: The re-emergence of H1N1 influenza virus in 1977: A cautionary tale for estimating divergence times using biologically unrealistic sampling dates. *PLoS ONE* 2010; 5:2-5
174. Williams S: BioHub network aims to advance sharing of pathogens for research. *The Scientist (LABX Media Group)*, Jun 6, 2021. [https://www.the-scientist.com/news-opinion/biohub-network-aims-to-advance-sharing-of-pathogens-for-research-68849]
175. Witte MH & Daley SK: SARS-CoV-2/COVID-19, lymphatic vessels, lymph, and lymphology. *Lymphology* 2020; 53:97-8
176. Wu Q, Xing Y, Shi L, Li W, Gao Y, Pan S, et al: Coinfection and other clinical characteristics of COVID-19 in Children. *Pediatrics* 2020; 146:e20200961
177. Wu X, Nethery RC, Sabath MB, Braun D, Dominici F: Air pollution and COVID-19 mortality in the United States: Strengths and limitations of an ecological regression analysis. *Sci Adv* 2020; 6:eabd4049
178. Xia B, Shen X, He Y, Pan X, Liu FL, Wang Y et al.: SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target. *Cell Res* 2021; 31:847-60
179. Xu H, Shi X, Li X, Zou J, Zhou C, Liu W et al.: Neurotransmitter and neuropeptide regulation of mast cell function: A systematic review. *J Neuroinflammation* 2020; 17:356
180. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng et al.: High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. *Int J Oral Sci* 2020; 12:8
181. Yang N & Shen HM: Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19. *Int J Biol Sci* 2020; 16:1724-31
182. Yilla M, Harcourt BH, Hickman CJ, McGrew M, Tamin A, Goldsmith CS et al.: SARS-coronavirus replication in human peripheral monocytes/macrophages. *Virus Res* 2005; 107:93-101
183. Zamir M, Goswami R, Salzer D, Shoemaker JK: Role of vascular bed compliance in vasomotor control in human skeletal muscle. *Exp Physiol* 2007; 92:841-8
184. Żelechowska P, Agier J, Różalska S, Wiktorska M, Brzezińska-Błaszczyk E: Leptin stimulates tissue rat mast cell pro-inflammatory activity and migratory response. *Inflamm Res* 2018; 67:789-99
185. Zeng Q, Li YZ, Dong SY, Chen ZT, Gao XY, Zhang H et al.: Dynamic SARS-CoV-2-specific immunity in critically ill patients with hypertension. *Front Immunol* 2020; 11:596684
186. Zhuang X, Silverman AJ, Silver R: Brain mast cell degranulation regulates blood-brain barrier. *J Neurobiol* 1996; 31:393-403
187. Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruville DE, Spudich S: Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: A review. *JAMA Neurol* 2020; 77:1018-27

Correspondence:

Gottfried R.S. Treviranus, MD  
BipoSuisse - Psychiatrische Praxis  
Vereinsweg 11, CH 3012 Berne, Switzerland  
E-mail: bipo Suisse@bluewin.ch